News

The successful completion and the milestone payment “provide Galimedix with an important operational runway to proceed with plans for additional clinical development in Alzheimer’s disease and other indications."

US eye medication shortages make up a sizable share of active drug shortages and last longer, driven by manufacturing issues, weak generics and unclear causes.

The manufacturer notes that TECNIS PureSee is the first US EDOF IOL cleared by the FDA without contrast sensitivity cautions.

For Jeffry D. Gerson, OD, FAAO, an early fascination with retinal disease—sparked during residency and shaped by mentorship and emerging OCT technology—led to a career focused on education and OD-MD collaboration.

The phase 2a study looks at retinal vascular diseases, including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO).

FDA greenlights first human trial of SVT-001, a regenerative cell therapy aiming to restore vision for patients with rare familial drusen.

Leng discusses preliminary results from an ongoing study investigating the interaction between pegcetacoplan and anti-VEGF treatments in patients with GA.

Steffen Schmitz-Valckenberg, MD, discusses how optical coherence tomography-based models may enable rapid, noninvasive assessment of functional loss in GA.

In the latest episode of The Retina TL;DR, host Christina Y. Weng, MD, MBA, FASRS, talks with Dr. Khanani about new retinal gene therapy trials, covering safety, delivery, and ways to reduce treatment burden.

Early clinical experience highlights considerations for patient selection, surgical technique, and long-term monitoring in retinal disease.

Under the US agreement, OPUVIZ (aflibercept-yszy), a biosimilar to Eylea (aflibercept) 2 mg, may launch in January 2027.

The 22nd International Scientific Symposium on Ophthalmic Imaging will take place September 18 to 19, 2026 in Singapore, featuring sessions on multimodal imaging, OCT, AI, and next-generation imaging technologies.

The group recommends more precise language such as “physicians” and “clinicians” to reflect medicine’s humanistic and professional responsibilities.

The results of a multicenter controlled clinical trial showed that the device resulted in “a significant improvement in visual acuity (VA) from baseline to month 12.

The deal will see MeiraGTx assume development rights to ZipBio’s experimental therapies targeting the complement pathway in geographic atrophy (GA).

Tenpoint Therapeutics’ YUVEZZI, projected to launch in the US in Q2 2026, represents the first fixed-dose combination eye drop developed to enhance near vision through pupil modulation with once-daily administration.

Optoretinography is an emerging technology used to test light-evoked photoreceptor activity.

Imaging and biomarkers are driving earlier, more individualized GA treatment

The JADE clinical study enrolled more than 160 patients with diabetic macular edema (DME) or wet (neovascular) age-related macular degeneration (wAMD).

When no retina podcast was available, Jayanth Sridhar, MD, created one—and learned lessons about branding, bandwidth, and mentorship along the way.

Researchers uncover a DNA repair mechanism in Greenland sharks that preserves their vision for centuries, offering insights into longevity and eye health.

Strategies for treatment intervals, drug selection, and patient expectations.

David S. Boyer, MD, outlines changes in GA evaluation, the role of complement inhibition, monitoring for neovascular conversion, and emerging therapies.

Nanoscope's new patent enhances its innovative MCO technology, promising vision restoration for retinal degeneration with strong safety results and market potential.

A recent study represents a step forward in investigations of the retinal layers as they are affected by glaucoma.

The Part B dose-expansion portion is evaluating SB-007 for the treatment of Stargardt disease.